AR103902A1 - Métodos para preparar buprenorfina - Google Patents

Métodos para preparar buprenorfina

Info

Publication number
AR103902A1
AR103902A1 ARP160100641A ARP160100641A AR103902A1 AR 103902 A1 AR103902 A1 AR 103902A1 AR P160100641 A ARP160100641 A AR P160100641A AR P160100641 A ARP160100641 A AR P160100641A AR 103902 A1 AR103902 A1 AR 103902A1
Authority
AR
Argentina
Prior art keywords
salts
peaks
buprenorphine
acetate
impurities
Prior art date
Application number
ARP160100641A
Other languages
English (en)
Original Assignee
Rhodes Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhodes Tech filed Critical Rhodes Tech
Publication of AR103902A1 publication Critical patent/AR103902A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)

Abstract

Sales de acetato de buprenorfina y sus anhidros, solvatos, hidratos y formas cristalinas y en la que las sales de acetato de buprenorfina se encuentran esencialmente libres de impurezas. Método para preparar las sales de acetato, la base libre de buprenorfina preparada a partir de las sales de acetato, otras sales preparadas a partir de la base libre y las composiciones farmacéuticas de estas esencialmente libre de impurezas. Reivindicación 9: La forma cristalina de la reivindicación 8 caracterizada por un patrón de difracción de rayos X en polvo obtenido mediante exposición a radiación CuKa que comprende picos a ángulos 2q sustancialmente equivalentes a al menos los picos a 16,21 y 18,70, y con al menos un pico adicional a un ángulo 2q sustancialmente equivalente a al menos uno de los picos a 8,77, 10,31 ó 18,47.
ARP160100641A 2015-03-10 2016-03-10 Métodos para preparar buprenorfina AR103902A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562131114P 2015-03-10 2015-03-10

Publications (1)

Publication Number Publication Date
AR103902A1 true AR103902A1 (es) 2017-06-14

Family

ID=55524412

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100641A AR103902A1 (es) 2015-03-10 2016-03-10 Métodos para preparar buprenorfina

Country Status (19)

Country Link
US (6) US10406152B2 (es)
EP (1) EP3283490A1 (es)
JP (2) JP6660399B2 (es)
KR (2) KR20170137738A (es)
CN (1) CN107660207B (es)
AR (1) AR103902A1 (es)
AU (2) AU2016230750B2 (es)
BR (1) BR112017019357A2 (es)
CA (2) CA3104099A1 (es)
CO (1) CO2017009130A2 (es)
EA (1) EA201792014A1 (es)
IL (1) IL254384A0 (es)
MA (1) MA45902A (es)
MX (1) MX2017011606A (es)
NZ (1) NZ735736A (es)
PH (1) PH12017501641A1 (es)
SG (1) SG11201707350TA (es)
TW (2) TW202037597A (es)
WO (1) WO2016142877A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015023036A2 (pt) 2013-03-15 2017-11-14 Univ Leland Stanford Junior método para preparar um produto alcaloide benzilisoquinolina e célula microbiana engenheirada que produz um produto alcaloide benzilisoquinolina
US11124814B2 (en) 2013-11-04 2021-09-21 The Board Of Trustees Of The Leland Stanford Junior University Benzylisoquinoline alkaloid (BIA) precursor producing microbes, and methods of making and using the same
AU2016230750B2 (en) * 2015-03-10 2019-05-30 Rhodes Technologies Acetate salt of buprenorphine and methods for preparing buprenorphine
CA2983419A1 (en) 2015-05-04 2016-11-10 The Board Of Trustees Of The Leland Stanford Junior University Benzylisoquinoline alkaloid (bia) precursor producing microbes, and methods of making and using the same
IL255136B2 (en) 2015-05-08 2023-09-01 Univ Leland Stanford Junior Methods for generating epimerases and benzylisoquinoline alkaloids
AU2017345328C1 (en) 2016-10-18 2023-03-02 Antheia, Inc. Methods of producing nor-opioid and nal-opioid benzylisoquinoline alkaloids
BR112020002050A2 (pt) 2017-08-03 2020-09-08 Antheia, Inc. epimerases engenheiradas alcaloides benzilisoquinolina e métodos de produção de alcaloides benzilisoquinolina
KR20210021459A (ko) * 2018-05-11 2021-02-26 에일러 파마슈티컬스 아이엔씨. 오래 지속되는 주사용 제제와 부프레노핀 유도체
WO2023246865A1 (en) * 2022-06-24 2023-12-28 Alar Pharmaceuticals Inc. Stable pharmaceutical composition of buprenorphine and preparation method and use thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3275638A (en) * 1966-09-27 Chjcoo-
US2191786A (en) 1938-03-18 1940-02-27 C A Miketta Continuous process for making adipic acid
BE466549A (es) 1945-07-17
US3355486A (en) 1965-01-08 1967-11-28 Fmc Corp Continuous process of synthesizing amino-iminomethane-sulfinic acid
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
GB1312447A (en) 1969-05-14 1973-04-04 Nat Res Dev Method of continuous addition of a component to a chemical or biological system and apparatus therefor
US4217287A (en) 1971-10-06 1980-08-12 Gulf Research & Development Company Epoxidation of alpha-olefins
US3936462A (en) * 1972-05-26 1976-02-03 Sterling Drug Inc. 1,2,3,4,5,6-Hexahydro-1-oxo or hydroxy-3-acyl-2,6-methano-3-benzazocines and corresponding 1-esters thereof
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
GB1520139A (en) 1976-06-08 1978-08-02 Ferranti Ltd Gyroscopic apparatus
US4362870A (en) * 1980-01-16 1982-12-07 Regents Of The University Of Minnesota Selective opioid receptor alkylating agents
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4830028A (en) 1987-02-10 1989-05-16 R. J. Reynolds Tobacco Company Salts provided from nicotine and organic acid as cigarette additives
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
CA2002299A1 (en) * 1988-11-10 1990-05-10 Eugene G. Drust Compositions for the transdermal delivery of buprenorphine salts
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6344211B1 (en) 1994-12-24 2002-02-05 Lts Lohmann Therapie-Systeme Gmbh Transdermal absorption of active substances from subcooled melts
DE4446600A1 (de) 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
TW452907B (en) 1999-11-22 2001-09-01 Winbond Electronics Corp Testing device and method of positive mobile ion contamination
US6994827B2 (en) 2000-06-03 2006-02-07 Symyx Technologies, Inc. Parallel semicontinuous or continuous reactors
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US7560445B2 (en) 2005-07-06 2009-07-14 Taro Pharmaceuticals North America, Inc. Process for preparing malathion for pharmaceutical use
DE102006054731B4 (de) 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
JP2010511726A (ja) 2006-12-04 2010-04-15 ノランコ・インコーポレーテツド １４−ヒドロキシコデイノンの濃度が低いオキシコドンの製造方法
CA2671860C (en) 2006-12-11 2016-07-12 Alcon Research Ltd. Process for preparing substantially pure fluorescein
EP2311498A4 (en) * 2008-08-05 2013-07-24 Medrx Co Ltd EXTERNAL PREPARATION COMPRISING A FATTY ACID SALT OR A BENZOIC ACID SALT OF A PHARMACOLOGICALLY ACTIVE BASIC COMPONENT, AND PROCESS FOR PRODUCTION THEREOF
US8492547B2 (en) * 2009-07-09 2013-07-23 Mallinckrodt Llc Method for the enrichment of buprenorphine using chromatographic techniques
NZ609874A (en) * 2010-09-30 2014-10-31 Astrazeneca Ab Crystalline naloxol-peg conjugate
SG11201403162XA (en) 2011-12-12 2014-10-30 Lohmann Therapie Syst Lts Transdermal delivery system comprising buprenorphine
WO2013156850A1 (en) 2012-04-17 2013-10-24 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
AU2013205080B2 (en) 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
ES2748803T3 (es) * 2012-12-31 2020-03-18 Rhodes Tech Procedimiento para preparar 6,14-etenomorfinanos sustituidos en 7, 6,14-etanomorfinanos sustituidos en 7
DK2810646T3 (en) 2013-06-04 2016-10-31 Lts Lohmann Therapie Systeme Ag A transdermal
CN103408553B (zh) * 2013-08-20 2016-02-03 宜昌人福药业有限责任公司 一种氢吗啡酮酸式盐的精制工艺
US8846923B1 (en) * 2013-12-18 2014-09-30 Cody Laboratories, Inc. Preparation of 14-hydroxycodeinone sulfate
AU2016230750B2 (en) * 2015-03-10 2019-05-30 Rhodes Technologies Acetate salt of buprenorphine and methods for preparing buprenorphine

Also Published As

Publication number Publication date
MA45902A (fr) 2019-06-19
TW202037597A (zh) 2020-10-16
US20170197975A1 (en) 2017-07-13
EA201792014A1 (ru) 2018-01-31
BR112017019357A2 (pt) 2018-06-05
US20180235955A1 (en) 2018-08-23
WO2016142877A1 (en) 2016-09-15
MX2017011606A (es) 2017-10-26
US10874662B2 (en) 2020-12-29
KR20170137738A (ko) 2017-12-13
AU2016230750A1 (en) 2017-10-12
JP2020033359A (ja) 2020-03-05
CN107660207B (zh) 2020-09-29
JP6660399B2 (ja) 2020-03-11
IL254384A0 (en) 2017-11-30
US20190314364A1 (en) 2019-10-17
CA2977732C (en) 2021-02-23
CA2977732A1 (en) 2016-09-15
US20210046066A1 (en) 2021-02-18
US10406152B2 (en) 2019-09-10
AU2016230750B2 (en) 2019-05-30
NZ735736A (en) 2019-02-22
TWI699367B (zh) 2020-07-21
US10278967B2 (en) 2019-05-07
KR20200045010A (ko) 2020-04-29
EP3283490A1 (en) 2018-02-21
CO2017009130A2 (es) 2017-11-21
US9926329B2 (en) 2018-03-27
AU2019203308A1 (en) 2019-05-30
CA3104099A1 (en) 2016-09-15
CN107660207A (zh) 2018-02-02
US20180162866A1 (en) 2018-06-14
PH12017501641A1 (en) 2018-02-12
SG11201707350TA (en) 2017-10-30
US10835528B2 (en) 2020-11-17
JP2018507882A (ja) 2018-03-22
US20190298713A1 (en) 2019-10-03
TW201639856A (zh) 2016-11-16

Similar Documents

Publication Publication Date Title
AR103902A1 (es) Métodos para preparar buprenorfina
CO2017012786A2 (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2016001287A1 (es) Benzamidas sustituidas y procedimiento para su uso
MX2017013801A (es) Métodos para tratar el cáncer.
DOP2016000299A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1
PE20201444A1 (es) Polimorfos cristalinos de la base libre de 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metoxi)benzaldehido
AR085650A1 (es) Formas solidas de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona, y sus composiciones farmaceuticas y usos
IL281220A (en) Process for preparing vaccine compositions
AR077203A1 (es) Forma polimorfica d del acetato de bazedoxifeno, composiciones farmaceuticas que la contienen metodo para prepararla y uso del mismo para tratar enfermedades mediadas por moduladores selectivos de receptores estrogenicos (serms)
CO2017008600A2 (es) Análogos de desacetoxitubulisina h, composiciones y método de producción de los mismos
CL2017002354A1 (es) Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd.
CR20150456A (es) Sal abexinostate novedosos asociados en forma cristalina, procedimiento de preparación y composiciones farmacéuticas que los contienen
MX2018007083A (es) Sintesis diaestereoselectiva de derivados de fosfato y del profarmaco de gemcitabina nuc-1031.
CY1124083T1 (el) Κρυσταλλικες μορφες ενος ανταγωνιστη υποδοχεα ανδρογονων, μεθοδος παρασκευης και χρηση αυτων
AR101368A1 (es) Forma cristalina de sofosbuvir y proceso para su preparación
EP3557955C0 (en) METHOD FOR PREPARING A TARGET FOR THE GENERATION OF RADIOACTIVE ISOTOPES AND TARGET OBTAINED
PH12015502122A1 (en) Sovaprevir polymorphs and methods of manufacturing thereof
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda
AR082435A1 (es) Valsartan altamente cristalino
PT3825307T (pt) Métodos para a síntese de dextrometorfano deuterado
WO2015197860A3 (en) Thapsigargin analogues and methods of preparing them
UY35945A (es) Derivados de azaindol
MX2017003607A (es) Sales de clorhidrato de aluminio que exhiben un pico 1 sec alto.
AR107441A1 (es) Forma cristalina de cobicistat
BR112018008319A2 (pt) formulação de fviii